Logo
x

Search

Subscribe Now

Verona Pharma

Verona Pharma’s Ohtuvayre (Ensifentrine) Receives the US FDA's Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

Verona Pharma’s Ohtuvayre (Ensifentrine) Receives the US FDA's Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

  • June 26, 2024
Verona Pharma Reports the US FDA Acceptance of NDA for Ensifentrine to Treat Chronic Obstructive Pulmonary Disease

Verona Pharma Reports the US FDA Acceptance of NDA for Ensifentrine to Treat Chronic Obstructive Pulmonary Disease

  • September 12, 2023
Verona Pharma Reports P-III Trial (ENHANCE-1) Results of Ensifentrine for the Treatment of Chronic Obstructive Pulmonary Disease

Verona Pharma Reports P-III Trial (ENHANCE-1) Results of Ensifentrine for the Treatment of Chronic Obstructive Pulmonary Disease

  • December 21, 2022
Verona Pharma Reports Completion of Enrollment for Ensifentrine in P-III (ENHANCE-2) Trial to Treat COPD

Verona Pharma Reports Completion of Enrollment for Ensifentrine in P-III (ENHANCE-2) Trial to Treat COPD

  • January 24, 2022
PharmaShots Weekly Snapshots (June 07 - 11, 2021)

PharmaShots Weekly Snapshots (June 07 - 11, 2021)

  • June 11, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.